伊尼妥单抗治疗HER2阳性乳腺癌肝寡转移1例并文献复习 .pdfVIP

20235010 Cancer Res Prev Treat,2023,Vol.50,No.101029

肿瘤防治研究年第卷第期··

doi:10.3971/j.issn.1000-8578.2023.23.0430病例报道

··

伊尼妥单抗治疗HER2阳性乳腺癌肝寡转移

1例并文献复习

11121

谢小凤，白雪，蓝晓凤，李木丽，杜彩文

InetetamabTreatmentforLiverOligometastasesofHER2-PositiveBreastCancer:A

CaseReportandLiteratureReview

11121

XIE Xiaofeng

, BAI Xue, LAN Xiaofeng, LI Muli, DU Caiwen

1.DepartmentofMedicalOncology,NationalCancerCenter/NationalClinicalResearch

CenterforCancer/CancerHospitalShenzhenHospital,ChineseAcademyofMedical

SciencesandPekingUnionMedicalCollege,Shenzhen518116,China;2.Pathology

DepartmentofNationalCancerCenter/NationalClinicalResearchCenterforCancer/Cancer

HospitalShenzhenHospital,ChineseAcademyofMedicalSciencesandPekingUnion

MedicalCollege,Shenzhen518116,China

CorrespondingAuthor:DUCaiwen,E-mail:*****************

Funding:Scientific Research Project of National Cancer Center/National Clinical Research Center for 

Cancer/Cancer Hospital  Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union 

Medical College, Shenzhen (No. E010322029) 

Competinginterests: The authors declare that they have no competing interests.

关键词：伊尼妥单抗；HER2阳性乳腺癌；肝寡转移；靶向治疗；局部治疗

()(OSID)

R737.9                                                 

中图分类号：开放科学资源服务标识码：  

0 引言寡转移的综合治疗手段，以期改善该类患者的生

根据2020年全球癌症报告数据，乳腺癌已成活质量，提高总生存期。

为全球第一高发恶性肿瘤，其中全球18.4%乳腺

[1]HER21 病例资料

癌新发病例在中国。阳性乳腺癌约占所有

乳腺癌的15%~20%，它侵袭性更高，更容易发